Screening Schedules and Microvascular Disease

CDCES Certified Diabetes Care and Education Specialist

Track your progress as you read

Finished sections get a check mark.

1 Introduction & the CDCES Exam

About the CDCES Credential & Current Exam Facts The July 2024 Exam Content Outline & Domain Weights The ADCES7 Self-Care Behaviors Framework

2 Pathophysiology, Classification & Diagnosis

Normal Glucose Regulation and the Pathophysiology of T1DM and T2DM Classification and Diagnostic Criteria Risk Factors and Primary Prevention Treatment Goals and Glycemic Targets

3 Assessment: History, Physical & Data

Health History & Diabetes-Specific Physical Assessment Interpreting Diabetes Measures & Laboratory Data Social Determinants of Health & Psychosocial Wellbeing

4 Assessing Self-Management & Learning

Assessing Self-Management Behaviors & Knowledge Assessing Technology Use, Problem-Solving & Risk-Reduction Behaviors Assessing Learning: Goals, Readiness to Change & Literacy Learning Considerations & Barriers

5 Developing the Education & Care Plan

Developing the Individualized Education/Care Plan Instructional Methods & Person-Centered Teaching Strategies SMART Goals, Behavior-Change Theory & Motivational Interviewing

6 Nutrition Therapy

Nutrition Recommendations & Eating Patterns Carbohydrate Counting & Insulin-Food Timing Fats, Protein, Alcohol & Dietary Supplements Food Labels, Weight Management & Special Nutrition Considerations

7 Physical Activity

Physical Activity Recommendations, Benefits, Challenges & Safety Activity Planning with FITT and Adjusting for Planned & Unplanned Activity

8 Pharmacologic Therapy

Insulin — Types, Pharmacokinetics & Delivery Systems Non-Insulin Glucose-Lowering Agents Guideline-Based Medication Selection Medication Titration & Immunizations for People with Diabetes

9 Monitoring

Glucose Monitoring: SMBG, CGM & Time in Range A1C and Ketone Monitoring Cardiometabolic and Organ System Monitoring

10 Acute Complications

Hypoglycemia Hyperglycemia, DKA, and HHS

11 Chronic Complications

Screening Schedules and Microvascular Disease Macrovascular Disease and Lower-Extremity Foot Care Infections, Dental Disease, Sexual Dysfunction, and Other Comorbidities

12 Special Situations & Populations

Sick-Day Management, Surgery, Travel & Emergency Preparedness Special Populations Across the Lifespan Preconception, Pregnancy, Postpartum & Gestational Diabetes Daily Living, Psychosocial Wellbeing & Safety

13 Evaluation & Documentation

Evaluating Intervention Effectiveness & Outcomes Documentation, Plan Revision & Referral

14 Standards, Guidelines & Professional Practice

National Standards for DSMES and the National DPP Applying Evidence-Based Practice Guidelines Population Health, Health Equity & Advocacy

Screening Schedules and Microvascular Disease

Key Takeaways Explain This Topic AI

Type 1 diabetes requires an initial dilated eye exam within 5 years of diagnosis; type 2 diabetes requires one at diagnosis; both are then screened annually.

Annual screening with both UACR and eGFR begins at diagnosis for type 2 diabetes and 5 years after diagnosis for type 1 diabetes.

An ACE inhibitor or ARB is strongly recommended for a UACR of 300 mg/g or higher and/or an eGFR under 60 mL/min/1.73 m-squared.

Distal symmetric polyneuropathy is screened annually using history plus the 10-gram monofilament, vibration sense, pinprick, and ankle reflexes, on the same 5-year/at-diagnosis schedule as retinopathy.

Diabetes increases the risk of both cataracts and open-angle glaucoma, which are detected during the same comprehensive dilated eye exam used for retinopathy screening.

Last updated: July 2026

Why Chronic Complications Screening Matters

Chronic diabetes complications accumulate silently over years of hyperglycemia-driven vascular and neural injury. Mapped to the ADCES7 "Reducing Risks" self-care behavior, the CDCES's job is to know the exact screening schedule, explain why each test matters, and trigger referrals before damage becomes irreversible vision loss, kidney failure, or amputation. The CBDCE outline tests chronic complications and comorbidities as a single scored task within Care and Education Interventions (II.C.6), and screening timing is among the most testable details in this domain.

Two patterns unify almost every microvascular screening rule below. First, type 1 diabetes (T1DM) follows a "5-year rule": clinically detectable microvascular damage takes years of sustained hyperglycemia to appear, so screening begins 5 years after diagnosis. Second, type 2 diabetes (T2DM) typically has years of undiagnosed hyperglycemia before diagnosis, so screening begins at the moment of diagnosis. Once screening starts, the default repeat interval is annual for all four microvascular categories covered here.

Retinopathy Screening

People with T1DM should have an initial dilated, comprehensive eye examination within 5 years of diagnosis. People with T2DM should have their initial dilated eye exam at the time of diagnosis, because retinopathy is often already present at that point. Both groups then need annual dilated exams performed by an ophthalmologist or optometrist. If one or more annual exams show no retinopathy and glycemic indicators are at goal, the interval may be extended to every 1-2 years; if retinopathy is present or progressing, exams must occur more frequently, at the treating eye specialist's direction.

Diabetic retinopathy progresses from mild or moderate nonproliferative disease (microaneurysms, dot-blot hemorrhages) to proliferative disease (neovascularization, vitreous hemorrhage, tractional retinal detachment), and can be complicated at any stage by diabetic macular edema, a leading cause of vision loss in people with diabetes. Anti-VEGF injections are now first-line therapy for center-involving macular edema and for many cases of proliferative disease; panretinal photocoagulation remains an option for proliferative retinopathy. Pregnancy accelerates retinopathy progression, so a comprehensive eye exam is recommended preconception or during the first trimester for people with preexisting diabetes, with close follow-up continuing through pregnancy and the first postpartum year.

Nephropathy Screening

Annual quantitative screening with both a urine albumin-to-creatinine ratio (UACR) and an estimated glomerular filtration rate (eGFR) begins at diagnosis for T2DM and 5 years after diagnosis for T1DM, then continues annually thereafter. UACR is categorized as normal (under 30 mg/g), moderately increased (30-299 mg/g, formerly called "microalbuminuria"), or severely increased (300 mg/g or higher, formerly "macroalbuminuria"); eGFR is staged using standard chronic kidney disease categories.

An ACE inhibitor or ARB is recommended for people with hypertension and moderately increased albuminuria (UACR 30-299 mg/g), and strongly recommended for severely increased albuminuria (UACR 300 mg/g or higher) and/or an eGFR under 60 mL/min/1.73 m-squared, titrated to the maximum tolerated dose to slow progression and reduce cardiovascular events. Reducing UACR by more than 30% from baseline, or to below 300 mg/g, is associated with better kidney and cardiovascular outcomes. SGLT2 inhibitors add independent kidney and cardiovascular protection and are recommended for eligible people with chronic kidney disease regardless of glycemic control.

Neuropathies

Distal symmetric polyneuropathy (DSPN), the most common diabetic neuropathy, should be assessed annually using history and simple clinical tests, on the same schedule as retinopathy and nephropathy: starting 5 years after diagnosis in T1DM, and at diagnosis in T2DM. The bedside exam combines the 10-gram monofilament (tests loss of protective sensation), vibration sense (128-Hz tuning fork), pinprick sensation, and ankle reflexes. Peripheral sensory neuropathy is the single most common contributing cause of foot ulceration, present in roughly three-quarters of ulcer cases.

Autonomic neuropathy symptoms and signs should be assessed on the same schedule, starting at diagnosis for T2DM and 5 years after diagnosis for T1DM, then annually. Cardiovascular autonomic neuropathy presents as resting tachycardia and orthostatic hypotension; gastrointestinal autonomic neuropathy causes gastroparesis (early satiety, bloating, nausea, and unpredictable postprandial glucose excursions that complicate insulin timing); genitourinary involvement causes neurogenic bladder and contributes to sexual dysfunction; and sudomotor dysfunction causes dry skin and abnormal sweating patterns that raise fissure and infection risk.

Cataracts and Glaucoma

Diabetes raises the risk of cataracts, which occur earlier and more often than in the general population, and of open-angle glaucoma. Both are detected during the same comprehensive dilated eye exam used for retinopathy screening, which is why the exam is comprehensive rather than retinopathy-only.

Complication Type 1 DM start Type 2 DM start Repeat interval

Retinopathy (dilated eye exam) Within 5 years of diagnosis At diagnosis Annual; every 1-2 yr if no retinopathy and glycemia at goal

• Nephropathy (eGFR + UACR) 5 years after diagnosis At diagnosis Annual
• DSPN (history, 10-g monofilament, vibration, reflexes) 5 years after diagnosis At diagnosis Annual
• Autonomic neuropathy (symptoms/signs) 5 years after diagnosis At diagnosis Annual

The CDCES's teaching role is to make this table concrete for each person: schedule the referral, explain why a normal eye exam this year does not mean skipping next year, and connect an abnormal UACR result to medication changes, such as starting or titrating an ACE inhibitor, ARB, or SGLT2 inhibitor, rather than treating it as an isolated lab value.